DNA strand breaks and cell cycle perturbation in Herceptin treated breast cancer cell lines

Breast Cancer Research and Treatment

Volumn 70, Issue 2, 2001, Pages 123-129

  Mayfield, Scott ^a   Vaughn, James P ^a   Kute, Timothy E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Breast cancer; Cell cycle; HER 2; Herceptin

Indexed keywords

NEU DIFFERENTIATION FACTOR; PROTEIN P27; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; DNA STRAND BREAKAGE; FLOW CYTOMETRY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; ONCOGENE NEU; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; DNA DAMAGE; HUMANS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0035213562     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012999012192     Document Type: Article

References (13)

1. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
2. Differential responses of human tumor cell lines to anti-p 185HER2 monoclonal antibodies
3. Monoclonal antibody therapy of human cancer: Taking the HER2 proto-oncogene to the clinic
4. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
5. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
6. Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays
7. Cytochemistry for bromodeoxyuridine/DNA; analysis; stoichiometry and sensitivity
8. Addition of Herceptin to first line chemotherapy for HER2 over-expressing metastatic breast cancer markedly increases anticancer activity: A randomized multinational controlled phase III trial
9. Recombinant humanized anti-HER-2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu over-expressing human breast cancer xenografts
10. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
11. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
12. Oncogene-activated AKT directly phosphorylates the cyclin-dependent kinase inhibitor p 27 and mediates cell cycle progression
13. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer